# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
1 | 05-15-2024 | 03-31-2024 | 10-Q |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
FDA approves Incannex's Phase 2 trial for psilocybin-assisted psychotherapy in treating generalized anxiety disorder, follo...
Incannex Healthcare Inc. (NASDAQ:IXHL), (‘Incannex' or the ‘Company'), a clinical-stage pharmaceutical company developi...
- SEC Filing
Incannex Healthcare Inc., a cannabinoid and psychedelic medicine biotechnology company, announced the successful completion of ...
Psilocybin-assisted therapy shows promise in treating GAD. Denver trains first responders in psychedelic crisis intervention. H...